No information is available about the effects of oral atenolol, a cardioselective f-adrenergic blocking agent with no intrinsic sympathomimetic activity, on left ventricular function. Atenolol, 100 mg/day, was given to 12 hypertensive patients for 8 weeks, and its effects on mean arterial pressure (MAP), cardiac index (Cl) and ejection phase indexes of myocardial performance were examined by echocardiography. Echocardiographic studies were performed before treatment, after 4 weeks of placebo, and repeated after 4 and 8 weeks of atenolol therapy. MAP fell by 14% and 21% after 4 and 8 weeks, respectively. CI fell by 22% and 20% and stroke index (SI) fell by 11% and 7%. Calculated peripheral resistance did not change significantly. Fractional shortening, ejection fraction and normalized mean rate of circumferential fiber shortening did not change. The normalized mean posterior wall velocity decreased after 4 weeks but returned to pretreatment levels after 8 weeks. The septal velocity increased after 8 weeks. End-diastolic volume index (EDVI) did not change, and there was no relationship between changes in heart rate and EDVI.
ATENOLOL is a new f-adrenergic receptor blocking drug with cardioselective properties that has no intrinsic sympathomimetic action or membrane-stabilizing activity. It is effective in the treatment of hypertension.`4 In acute and long-term hemodynamic studies, atenolol produced a marked reduction in cardiac output (CO), with variable or little effect on calculated total peripheral resistance (TPR).5 Studies in animals have shown that atenolol has no negative inotropic effect.8 However, the effects of atenolol on myocardial contractility have been demonstrated less often in man and only in acute i.v. experiments. 9 10 Information regarding its effect on left ventricular (LV) function after oral therapy have not been reported.
Previous studies with f-adrenergic blocking drugs have shown lack of similarity in hemodynamic response between i.v. and long-term oral administration.,l 12 We studied the effects of oral atenolol therapy on arterial pressure, CO and LV contractile state in hypertensive patients.
Echocardiography was used in this study to measure LV dimensions and to assess LV function. Good correlation between angiocardiographic and echocardiographic measurements of LV dimensions and indexes of myocardial contractility has already been demonstrated. '3-17 Methods Twelve male patients with essential hypertension were studied on an outpatient basis. Secondary hypertension was excluded by the usual routine procedures.`8 All patients were asked to participate in the study voluntarily. They gave formal consent after a detailed explanation of the aims and objectives of investigation. Table 1 shows the clinical characteristics of the patients. Patients were excluded if they had severe sinus bradycardia, more than grade I atrioventricular block, congestive heart failure, bronchial asthma, uncontrolled diabetes mellitus, valvular heart disease, clinical and/or electrocardiographic evidence of coronary artery disease or radiologic evidence of cardiac enlargement, or if they were markedly obese or had severe chest deformity that made adequate echocardiographic examination impossible. Patients with malignant or accelerated hypertension (grade IV and III retinopathy) were also excluded.
Study Design
Each patient was followed initially for 4 weeks. All previous antihypertensive medication was discontinued and placebo was given. Blood pressure and heart rate (HR) were checked twice weekly in the supine and standing positions. If at the end of this 4week placebo pretreatment period supine diastolic blood pressure was greater than 95 mm Hg, the patient was included in the study. Only patients with very good, readable echocardiographic recordings were studied. Patients with poor records were excluded. During a further 4-8-week treatment period, all patients were started on a dose of 100 mg of atenolol daily.
Echocardiographic Studies
At the conclusion of the 4-week pretreatment (first placebo) period, each patient underwent echocardiographic evaluation as described previously. 19 These studies were performed under standard conditions in the morning, at the same hour of the day (9-10:30 1036 a.m.) after an overnight fast. Studies were made in a quiet room where lights were dimmed and minimal disturbance was allowed. The safety and the noninvasive nature of the procedure were explained to the patient. Each patient remained resting supine for 30 minutes before the start of echocardiographic examination. The head part of the examination table was elevated 30°above horizontal. During recording, the patient's head and shoulders were elevated while he was lying in the left lateral position with his left arm turned up toward his head. This position was reproducible because the angle of elevation and the degree of left lateral rotation were constant.
The echocardiograms were recorded with a Unirad ultrasonoscope model 489 Sono III-GZD using a 2.25-MHz transducer with an active diameter of 13 mm and internal focus 4-7 cm, with a repetition rate of 1000 impulses/sec. The ultrasonoscope was coupled to a strip-chart recorder. Recordings were obtained at paper speed of 50 mm/sec and, when necessary, 100 mm/sec. Each patient had an ECG recorded simultaneously with the echocardiogram. Particular care was taken to standardize the pathway of the ultrasonic beam through the left ventricle, to correctly identify the internal and external surfaces of the LV walls. Measurements of LV dimensions were made at an angle in which fragmental echoes of the mitral valve were seen. The interventricular septum and posterior wall endocardial echoes could then be recorded at the level of the chordae ( fig. 1 ). Patients were asked to breath quietly during recording. Inconsistency in placement and technique of handling the echocardiographic transducer were avoided by keeping a record for each patient indicating the transducer position selected at the first visit. To obtain consistent and reproducible recordings, the standard intercostal space technique was used. The transducer was held perpendicular to the chest wall, with only slight medial or lateral but no superior or inferior angulation, while permitting recording of the anterior mitral leaflet. 20 Care was taken to reproduce the identical minor axis chord and largest ventricular dimension by scanning in the direction of both major and minor axes at each subsequent visit.
Measurements and Calculations
The LV echocardiographic dimensions were measured from the endocardial echo of the posterior wall to the endocardial echo of the left side of the interventricular septum. Wall and cavity measurements were made by using a leading edge method (from the anterior most edge of endocardial lines) and by using the thinnest continuous echo lines. Following the recommendations of the American Society of Echocardiography,2' the diameter at end-diastole (EDD) was measured at the onset of the QRS complex and diameter at end-systole (ESD) was measured at the point of the smallest distance separating the septum from the posterior wall ( fig. 1 ). The LV ejection time (LVET) was measured from the aortic valve echogram or from a simultaneously recorded external carotid arterial pulse tracing. Posterior LV wall excursion (PWE) was measured from the most posterior point of the LV endocardial tracing to the most anterior point in systole. Similar points at the beginning and peak of the septal systolic excursion were selected to measure septal excursion (IVSE).
Echocardiographic measurements were made directly with a millimeter ruler and calipers. The raw measurements were multiplied or divided by a conversion factor that expressed how many real millimeters a 1-cm standard occupies on the echocardiogram. LV volumes were derived by cubing EDD and ESD. The difference between the end-diastolic volume 1037 VOL 62, No 5, NOVEMBER 1980 (EDV) and end-systolic volume (ESV) was the LV stroke volume (SV). CO was derived by multiplying the HR in the simultaneous electrocardiographic record by the SV. The ejection fraction (EF) was derived as
EDV -ESV EDV
The fractional shortening (FS) was calculated as
EDD-ESD EDD
The normalized mean rate of circumferential fiber shortening (Vcf) (circ/sec) was calculated as
EDD -ESD LVET X EDD
The normalized mean posterior wall velocity (Vpw) (sec' ) was calculated as PWE LVET X EDD' Similarly, the normalized mean interventricular septal velocity (Vivs) (sec-') was calculated as IVSE LVET X EDD All calculations were made using the average obtained from eight cardiac cycles.
Echocardiographic measurements were determined independently by two of the investigators and the results were compared. Only twice were measurements not consistent, and in both cases the echocardiographic records were reexamined by both investigators. One investigator had difficulty defining the LV posterior wall endocardium.
Blood pressure was recorded immediately before each study by two observers with a standard sphygmomanometer cuff. The mean of three blood pressure readings (same arm) after 30 minutes of supine rest was recorded. Diastolic blood pressure was measured at phase V Korotkoff sounds. The mean arterial pressure (MAP) was calculated by adding one-third the pulse pressure to the diastolic blood pressure (DBP):
where SBP = systolic blood pressure.
Corrections were made to account for changes in body surface area (BSA). The cardiac index (CI), stroke index (SI) and the end-diastolic volume index (EDVI) were obtained by dividing the CO, SV and EDV by the BSA, respectively. The CI and calculated mean blood pressure22 were used to estimate the total peripheral resistance. 23 The TPR was determined indirectly and was derived from the equation:
TPR.m2 (Us) = MAP/CT
Echocardiographic studies were repeated in all patients after 4 weeks of antenolol treatment and again for the third time after 8 weeks in eight patients.
Reproducibility Studies
The reproducibility of echocardiographic measurernents was examined in seven healthy, normotensive Calculations of averages, paired t tests, analysis of variance, correlation coefficients, and statistical significance of results were performed by standard methods. 24 The threshold of significance wasp < 0.05.
Results
The results of the present study are shown in tables 2 and 3 and in figures 2-10.
Arterial Pressure
The blood pressure was reduced in all subjects by 10% or more. The pretreatment MAP was 141 ± 4.79 mm Hg (mean ± SEM) (range 115-170 mm Hg). At the conclusion of 4 weeks of atenolol treatmient (100 mg/day), MAP fell to 121 ± 4.72 mm Hg (range 101-155 mnm Hg), a 14% reduction. After 8 weeks of therapy MAP fell by 30 ± 2.41 mm Hg, 21% from the pretreatment level (table 2 and 
NS NS
Abbreviations: MAP = mean arterial pressure; HR heart rate; CI = cardiac index; SIstroke index; TPRtotal peripheral resistance; LVET = left ventricular ejection time; C = control after 4 weeks of placebo; 1 = atenolol therapy for 4 weeks; 2 = atenolol therapy for 8 weeks. Abbreviations: EDVI = end-diastolic volume index; FS = fractional shortening; EF = ejection fraction; Vcf -normalized mean rate of circumferential fiber shortening; Vpw = normalized mean posterior wall velocity; Vivs = normalized mean interventricular septal velocity; C = control measurements after 4 weeks of placebo; 1 = atenolol therapy for 4 weeks; 2 = atenolol therapy for 8 weeks. Measurements of Vcf were not available in all patients because precise measurements of left ventricular ejection time were difficult in some patients. was 71 ± 2.58 beats/min (range 58-84 beats/min). After 4 weeks of atenolol treatment it fell to 63 ± 2.54 beats/min (range 47-79 beats/min), an 1 1% reduction. The rate continued to fall, and after 8 weeks of therapy it was 61 ± 3.31 beats/min (range 45-70 beats/min), a 14% decrease from pretreatment HR.
Cardiac Index
The pretreatment CI was 4.58 ± 0.28 1/min/m2* fig. 4 ). The fall in CI was maintained at the eighth week of therapy; it was 3.30 ± 0.21 1/min/M2, a 20% decrease from initial control readings. CI fell from the pretreatment level in all patients except one, who had an increase of 0.65 1/min/M2. On the other hand, comparison with 4-week measurements showed an increase of CI in six patients and decrease in two ( fig. 3 ). There was no relationship between changes in CI and changes in MAP, but the changes were significantly 5 ).
Stroke Index
The pretreatment SI ranged between 45 and 95 ml/m2 (66 ± 4.87 ml/m2). Changes after atenolol treatment were variable and inconsistent ( fig. 3 ). At fig. 7 ). Other factors influencing cardiac function remained constant. A fall in MAP is expected to result in better LV ejection and a larger SI.
Total Peripheral Resistance
The pretreatment TPR index (TPRI) was 22-50 units/rM2 ( (fig. 2 ). The very large standard error of the mean made these changes insignificant.
Ejection Time
The LVET increased after 4 
End-diastolic Volume Index (EDVI)
The pretreatment EDVI ranged from 63-129 ml/m2 (93 ± 5.9 mI/m2). At the conclusion of 4 weeks treatment the changes were insignificant and inconsistent. EDVI decreased in seven patients, did not change in three and it increased in two. Similarly, after 8 weeks no significant or consistent changes were found ( fig. 8 , table 3 ). Changes in HR and EDVI were not related ( fig. 9 ).
Fractional Shortening
Changes in FS were insignificant after both 4 and 8 weeks of therapy. The pretreatment FS ranged between 22-49% (34.9 ± 2.16%). After atenolol treatment (4 weeks), FS decreased in six patients, increased in five and did not change in one, and it ranged between 25-44% (33.8 ± 1.66%). After 8 weeks changes were also inconsistent and insignificant. FS increased in five patients and decreased in three; the mean value was 35.3 ± 2.74% (table 3) .
Ejection Fraction EF did not change after atenolol treatment (table  3) . The pretreatment values ranged between 0.52-0.86 (0.71 ± 0.028). Figure 8 shows the variable and inconsistent changes in EF after 4 
Normalized Mean Vcf
Changes in Vcf after atenolol therapy were insignificant. The pretreatment values ranged from 0.52-1.60 circ/sec (1.13 ± 0.088 circ/sec). After 4 weeks of atenolol Vcf decreased by 0.12 ± 0.08 circ/sec, it decreased in eight patients and increased in three, and the average was 1.05 ± 0.078 circ/sec ( fig.  10 ). Measurements of Vcf were not available in all patients because it was sometimes difficult to get precise measurements of LVET. After 8 weeks Vcf was 1.19 ± 0.14 circ/sec. It decreased from pretreatment rates in three patients and increased in two ( fig.  10 ). Changes were not significant after either 4 or 8 weeks of treatment.
There was a positive correlation between the changes in Vcf and the changes in CI and SI (figs. 5 and 6), as stated previously. However, the fall in MAP and the changes in Vcf were not related.
Normalized Mean Posterior Wall Velocity (Vpw)
The Vpw decreased at the completion of 4 weeks of atenolol treatment; however, after 8 weeks it increased to the pretreatment level (table 3). The pretreatment Vpw varied between 0.52-1.0 sec`(0.82 ± 0.04 sec-'). After 4 weeks it decreased in nine patients, did not change in one and increased in one (range 0.52-0.89 sec-'). After 8 weeks, Vpw decreased from pretreatment levels in three patients and increased in two (range 0.60-1.1 sec-').
Normalized Mean Interventricular Septal Velocity (Vivs)
There was no significant change in Vivs after 4 weeks of atenolol treatment, but it increased at the end of the eighth week (table 3) . The pretreatment Vivs varied between 0.30-0.91 sec`. After 4 weeks it increased in seven patients and decreased in four (range 0.37-0.73 sec-'). After 8 weeks the Vivs increased in four patients and decreased in one (range 0.37-0.70 sec.-').
Reproducibility Table 4 shows changes in EDD, ESD, HR and CI 6 weeks apart in seven healthy, normotensive subjects. Difference in CI ranged from 1-15% (mean 6.9%).
To measure the accuracy of the method, a "homogeneity test" was done to the readings and was not significant.
The average difference between successive readings (temporal variation) was calculated and tested by the paired t test and was not significant. The temporal variation and interobserver variation were tested together by the analysis of variance "ANOVAR method" (two factors). Neither factor was statistically significant.
Discussion
Studies of LV function in hypertensive patients have been hampered because of the difficulty in conducting direct intraventricular studies in asymptomatic patients. When such studies are available, results have been questionable because the hemodynamic status may have been altered by premedication or the associated anxiety of the procedure. Echocardiography is noninvasive and a relatively simple and accurate method for measurements of cardiac dimensions and assessment of LV function. Studies at cardiac catheterization with LV angiography repeatedly confirmed the good correlation between echocardiographic and angiographic measurements in Abbreviations: EDD_= end-diastolic diameter; ESD = end-systolic diameter; HR = heart rate; CI = cardiac index; 1 and 2 refer to the initial and the second serial measurements after 6 weeks; SEM = standard error of the mean; SED = standard error of the difference.
patients without LV asynergy.11, 25 Because only small segments of the interventricular septum and posterior wall of the left ventricle are studied with standard time-motion echocardiography, an important assumption in calculating LV volumes is that the pattern of LV contraction is uniform and symmetric. We excluded patients with clinical or electrocardiographic evidence of coronary artery disease, a common cause of LV asynergy. Also, we excluded patients with cardiomegaly, an important source of error in calculating LV volumes by echocardiography. To avoid the effects of phasic respiration on LV dimensions and derived LV function,26 patients were asked to breathe quietly during recording and the average measurement of eight consecutive cardiac cycles was taken. The use of ejection phase indexes of myocardial performance in our study was based on data from previous observations. A linear correlation was found between echocardiographic ejection phase indexes, FS, EF, normalized mean Vcf, and similar angiographic measurements.`6 17, 27 Previous studies have shown that analysis of LV wall motion by echocardiography using the normalized velocity concept appears to be a rational and practical method for evaluating LV performance.27 Furthermore, ejection phase contractile indexes have been shown to provide a practical and physiologically reasonable means of assessing the level of basal myocardial contractile state,'8 and they were found to be superior and more reliable than isovolumic indexes of myocardial performance.28
Mechanism of Hypotensive Action of Atenolol
The present study supports the previously reported effectiveness of atenolol in lowering high blood pressure.'4 All patients had a reduction in resting blood pressure of 10% or more. At the conclusion of 4 weeks of atenolol therapy MAP fell by 20 mm Hg or 14%, and after 8 weeks it fell by 30 mm Hg, or 21% from the pretreatment level. The fall in blood pressure was secondary to a reduction in CI, the effect on calculated TPR was variable and insignificant. After 8 weeks of therapy and further reduction in arterial pressure there was a tendency of TPR to decline, but changes were not significant. On the other hand, there was no correlation between the fall in MAP and the reduction in CI; thus the changes in blood pressure and CI occurred independently. The study period was too short to find whether a progressive decline in peripheral resistance is the determining factor in the hypotensive action of atenolol, similar to that reported with propranolol."1 However, long-term studies in subjects treated with atenolol as the sole drug for 1 year showed that the changes in TPR were inconsistent and the mean value was almost unchanged. 7 The reduction in CI was due to both cardiac slowing and decrease in SI. The changes in HR and SI were only significant after 8 weeks of therapy but there was no significant difference in the degree of cardiac slowing or the fall in CI at the end of the fourth and eighth weeks.
The insignificant changes in the TPR and the marked reduction in CI and HR after atenolol therapy resemble those reported by Amery et al.5 in a shortterm study and those of Lund-Johanson' in a longterm hemodynamic evaluation. However, the relative decreases in HR in these studies were more pronounced -33% and 24%, respectively. Furthermore, changes in SI were at variance with those described by Lund-Johanson. 7 In his studies SI was higher after therapy than before. Our findings agree with acute studies' 9, 10 that showed a decrease or no change in SV. The difference in response to atenolol might be related to the greater degree of cardiac slowing in the Lund-Johanson observations compared with our findings. Slower HR in the presence of undisturbed venous return would allow a better filling of the heart. However, Robinson et al.9 found a significant fall in SV after i.v. atenolol during atrial pacing, with the HR maintained constant, and during spontaneous sinus rhythm. They concluded that the fall in CO was not purely rate-dependent.
Changes in Myocardial Contractility
Atenolol produced no significant change in the ejection phase indexes of myocardial performance.
The FS, EF and Vcf did not change during atenolol therapy. The normalized mean Vpw decreased only at the initiation of therapy and returned to the pretreatment level after 8 weeks. On the other hand, the normalized mean Vivs did not change after 4 weeks, but increased after 8 weeks. Studies in animals have shown that atenolol has no negative inotropic effect.8 However, acute i.v. studies in man showed a depression of isovolumic indexes of myocardial performance in both normal subjects and in patients with coronary artery disease.10 Ejection phase indexes were depressed significantly in coronary patients.
The EDVI did not change after atenolol treatment despite cardiac slowing. DeMaria et al.29 showed that in normal persons cardiac acceleration by atrial pacing produces a reduction in cardiac dimensions and increase in Vcf and that cardiac size was significantly affected by alterations in HR. A remarkably linear relation was consistently observed between increases in HR and alterations in measurements of cardiac size. 29 We found no relationship between EDVI and HR ( fig. 9 ). Atenolol might reduce cardiac venous filling, and thus, EDVI would not increase with cardiac slowing. This assumption could also explain the reduction in SI after atenolol therapy. Our studies demonstrate that atenolol given orally does not depress cardiac contractility, so reduction in SI must be due to mechanisms other than simple depression of cardiac function. Atenolol, like propranolol,'0'3 could produce contraction of blood volume. Either this factor alone or a redistribution of intravascular volume away from the heart secondary to an increase in venous distensibility that favors a diminution in venous return causes the fall in SI. A decrease in venous tone after f-adrenergic blockade with pindolol 1044 C IRCU LATION has been reported in hypertensive patients. 32 Although myocardial contractility plays a role in pump function, as shown by the presence of a positive correlation between changes in Vcf and changes in CI and SI, changes in venous filling are apparently overriding. There is considerable evidence that when the contractile state of the myocardium is normal, CO is dependent more on peripheral factors and the influence these factors exert on the ventricular preload and afterload, than on the contractile state of the myocardium. 33 The lack of depressant effect by atenolol on myocardial contractility has significant clinical importance, because a negative inotropic effect is not welcomed in patients with cardiac insufficiency or in borderline impairment of LV function. In a previous study4 we gave atenolol to hypertensive patients with cardiomegaly and incipient heart failure. The drug was safe and symptoms of cardiac decompensation improved with reduction in arterial pressure in spite of ,B-adrenergic blockade.
The effect of f-adrenergic blocking drugs on cardiac contractility cannot be explained simply in terms of establishment of f-adrenoceptor blockade and the associated withdrawal of sympathetic support. The mechanisms whereby these drugs alter cardiac contractility are complex. Recent investigations have shown that at least some of the 3-adrenoceptor antagonists interact with the plasma membrane in such a way that its capacity to store Ca++ for subsequent release is impaired and also reduce the capacity of the sarcoplasmic reticulum to accumulate Ca++ for subsequent release;34-36 hence, less Ca++ is made available for contraction. Atenolol might have a minimal effect on plasma membrane and Ca++ binding, which would explain the absence of a direct depressant effect on cardiac contractility.
In the basal resting state the sympathetic adrenergic system has minimal influence on cardiac performance; therefore, ,B-adrenergic blockade will influence cardiac contractility to a very small extent. Thus, in the absence of a direct cardiac depressant effect, it is not surprising that a f-adrenergic blocking drug like atenolol does not have a negative inotropic effect. onary patients. Variations in normal coronary anatomy are well recognized, including differences in the length of the left main coronary artery (LMCA) and the size and number of vessels present at its division.' These structures move with ventricular systole relative to the ultrasonic plane. Because of the current technical limitations in directly visualizing the LMCA, we have attempted to create a technique to analyze variations in tissue properties of this region by means other than direct visualization. The goal of this research is to develop a method to accentuate the differences between sound reflected from atherosclerotic and from normal tissue. This report describes the development of such a technique. The results of an initial prospective study using this method for the identification of coronary artery disease (CAD) in a large clinical population are presented. In addition, a basis for the change in reflectivity produced by atherosclerosis is presented and the potential clinical role of this type of research discussed.
Methods
To evaluate the effect of digital signal processing on the ability of echocardiography to detect changes in focal reflectivity produced by atherosclerosis, a commercially available, two-dimensional echocardiographic scanner was modified at Indiana University 1046 CIRCULATION
